| UHC Commercial Medical & Drug | Omvoh® (Mirikizumab-Mrkz) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-05-01 |
| UHC Commercial Medical & Drug | Qalsody® (Tofersen) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-05-01 |
| UHC Commercial Medical & Drug | Tremfya® (Guselkumab) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-05-01 |
| UHC Commercial Medical & Drug | Veopoz® (Pozelimab-Bbfg) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-05-01 |
| UHC Commercial Medical & Drug | Viltepso® (Viltolarsen) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-05-01 |
| UHC Commercial Medical & Drug | Vyondys 53® (Golodirsen) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-05-01 |
| BCBS Premera WA AK Clinical | Home Nutritional Support | 2026-05-01 |
| BCBS California | Genetic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment in Advanced Cancer | 2026-05-01 |
| BCBS California | Hippotherapy (Equine/Horse therapy) | 2026-05-01 |
| BCBS Louisiana | Closure Devices for Patent Foramen Ovale and Atrial Septal Defects | 2026-05-01 |